Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Apen-label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of BEBT-109 in Patients With EGFR Exon 20 Insertion Mutations in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06706713 is registered in ClinicalTrials.gov with BeBetter Med Inc as lead sponsor.

NCT NCT06706713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06706713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Apen-label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of BEBT-109 in Patients With EGFR Exon 20 Insertion Mutations in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
BeBetter Med Inc
Phase
Phase 2
Overall status
Recruiting
Start date
April 15, 2022
Completion date
June 30, 2026
Enrollment
200 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

egfr exon 20 insertion mutation, non-small cell lung cancer